Managing Antitrust Risks in ACOs, IPAs, CINs and PHOs

Manatt, Phelps & Phillips, LLP

Manatt, Phelps & Phillips, LLP

Editor’s Note: There is considerable overlap in the nature and goals of the “alphabet soup” of network structures—Accountable Care Organizations (ACOs), Independent Practice Associations (IPAs), Clinically Integrated Networks (CINs) and Physician Hospital Organizations (PHOs). Often, there is little practical difference among the network types, regardless of the latest popular acronym chosen as the label. They all present similar legal challenges to establishing, structuring and operating a successful provider network. In a recent webinar, Manatt decoded the acronyms—and explained, for both lawyers and nonlawyers, how to navigate the legal issues involved in launching and maintaining a provider network.

In part 1 of our article summarizing the webinar, we explained critical terminology, as well as reviewed entity formation issues. In part 2 of our summary, below, we focus on antitrust issues and risk management. Click here to view the webinar free, on demand, and earn CLE. Click here to download a free copy of the webinar presentation.


The key antitrust statute is Section 1 of the Sherman Act, which prohibits two types of agreements that unreasonably restrain competition:

  • Agreements that are per see illegal. There is no need to demonstrate actual anticompetitive impact. These types of agreements are always illegal. Examples include agreements between competitors to fix prices; allocate customers, markets or geographic territories; or boycott particular customers or suppliers.
  • Agreements considered under the rule of reason. For all agreements that are not per se illegal, there is the need to analyze the actual competitive impact of the agreement, as well as to consider procompetitive efficiencies.

Antitrust Issues and Provider Collaborations

All provider collaborations are agreements between independent parties that are subject to Section 1. The agreement that we are talking about here is the participating provider agreement. All collaborations between competing or potentially competing providers—including the documents providers sign to be part of a network entity—are potentially subject to per se liability.

Because provider networks typically want to engage in price negotiations with payers and enter into a single agreement covering the services of the entire group, the key antitrust concern is price fixing. If the agreement between competing providers is just to negotiate jointly, it could be considered a per se price-fixing agreement.  

To identify if there is an antitrust issue, it is critical to determine if there are competing providers in the network. Not all providers compete. Some offer different services. For example, orthopedists don’t compete with obstetricians. Others practice in different regions. Two primary care physicians (PCPs) don’t compete with each other if their practices are 150 miles apart. The bottom line is, however, that most networks are going to have competing providers in them.

It is important to remember that competition isn’t always obvious. There may be overlaps between different specialties. For example, some PCPs can provide some of the same services as a cardiologist. Multispecialty practices and federally qualified health centers can cloud the picture even more, because they can include a variety of providers and specialists. Telemedicine further complicates the issue, because it can create competition between providers, even if they practice in distant locations. The fact that certain providers are friendly and may even refer patients to each other does not mean that they are not competitors. In addition, hospitals may be part of the physician competitive set if they employ PCPs or specialists who compete with private practice physicians in the surrounding community.

Managing Antitrust Risk: Integration Models

Integration programs seek to achieve efficiencies, such as cost savings and quality improvements. There are three types of integration models—financial, clinical and hybrid (which includes elements of both financial and clinical integration). A network will avoid the per se price-fixing concern if the joint contracting is ancillary and necessary to achieve the efficiency goals of the integration. Joint contracting can’t be the primary purpose of the integration.

Over time, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have issued guidance on when an integrated network can engage in joint contracting, including the 1996 Healthcare Statements and the 2011 Medicare Shared Saving Program (MSSP) ACO Guidance. Nothing has been released from the agencies, however, since 2013.

Financial Integration

The 1996 Healthcare Statements define financial integration as a network of otherwise independent providers sharing financial risk in such a way that each member has an economic incentive to ensure that the network as a whole generates efficiencies that benefit consumers. Financial integration can’t be the goal. The goal has to be to creating meaningful prospects for improving efficiency, controlling costs, managing utilization and/or improving quality of care.

Substantial financial integration includes the concept of both upside and downside risks. There is no clear guidance on the exact level of risk that is required, although 15% is the common benchmark.

The 1996 guidance also sets out safety zones. If a collaboration falls within the safety zone, the agency is presuming that it will not have an anticompetitive impact. For exclusive physician networks, participants can constitute only 20% or less of each physician specialty in the relevant geographic area. If a network is nonexclusive, the number goes up to 30% or less. For a network to be considered nonexclusive, there must be evidence that its physicians can participate in and earn substantial revenue from other networks. Physicians also must be able to contract individually.

Networks outside the safety zone are judged under the rule of reason. The integration must be likely to produce significant efficiencies that benefit customers, and price agreements must be reasonably necessary to achieve those efficiencies. Where there is high market share, collaborations will face greater scrutiny to ensure they are producing the efficiencies, cost savings and quality improvements that would justify joint contracting.

Three Examples of Financial Integration

Following are examples illustrating three types of financial integration.

The first example is based on a 1980s-era approach, with fee-for-service payments being made by the health plan. The plan pays 80% of the claim but holds back 20% in a collective pool. If year-end performance metrics are achieved (or exceeded), the withheld funds (and possibly an additional bonus) are paid to the billing providers. This approach demonstrates the “skin in the game” required to be viewed as financially integrated.

The second example demonstrates full-risk capitation, sometimes referred to as population-based payments. Under full-risk capitation, the payer pays $100 per member per month to the network. The network entity pays participants’ fee-for-service claims or has the health plan pay on its behalf. At the end of the year, all the risk is held by the network entity, not by the health plan. The availability of funds for the network entity to pay all claims is based on the collective performance of the entire network. Therefore, the network is considered financially integrated.

In the third example, the payer pays the standard fee from its existing fee-for-service schedule. If aggregate claims payments for the year are less than the payer projects, the payer shares a percentage of the savings with the network entity in a year-end lump-sum payment. The network entity decides how the lump sum will be allocated to downstream providers. 

Clinical Integration

The 1996 Healthcare Statements define clinical integration as an “active and ongoing program to evaluate and modify the practice patterns by the network’s physicians and create a high degree of interdependence and cooperation among the physicians to control costs and ensure quality.” The definition is deliberately open-ended. The analysis focuses on the substance of what’s being done, not the exact form. The 1996 Healthcare Statements provide some examples—such as mechanisms to monitor and control utilization, the selective choice of network participants, and significant investment of monetary and human capital. But they don’t prescribe.

As with financial integration, the overall goal of a clinical integration program must be to create a meaningful prospect of jointly improving efficiency, controlling costs, better managing utilization and enhancing care quality. Any agreements on price must be “reasonably necessary” to realize these improvements.

In discussing clinical integration, it is important to be aware of alternative meanings when the term is used outside the antitrust context. For example, many use the term “clinical integration” when discussing healthcare reform to describe the tools needed to attain the Triple Aim.   

To add to the confusion, some states have their own definitions of clinical integration that may or may not be the same as the antitrust definition. It is important not to assume that the state regulators’ standard for clinical integration is sufficient to meet the DOJ’s and FTC’s definitions of the same term.

In this complex environment, how is it possible to determine if there is an antitrust problem with a clinically integrated entity? There are a number of possible approaches:

  • Review the FTC and DOJ guidance and make a determination.
  • Seek informal FTC and DOJ guidance to receive an off-the-record response. (The caveat to this approach is that the entity is now on the agencies’ radars.)
  • Seek a formal advisory opinion.
  • In extreme cases, apply for state-action protection. (Some states have Certificate of Public Advantage (COPA) processes for collaborations that meet state healthcare goals.)
  • Add financial integration to create a hybrid model.

Clinical Integration: Medicare ACO Policy Statement

The Medicare ACO Policy Statement applies to ACOs that intend to be or have been approved to participate in the Medicare Shared Savings Program (MSSP). It also applies to other ACO initiatives from the CMS Innovation Center (such as Pioneer ACO) and to Medicare ACOs that participate in commercial markets. It does not formally apply to non-Medicare ACOs. An ACO with the same features, however, is likely to satisfy clinical integration standards.

The primary point of the Medicare ACO Policy Statement is that the FTC and DOJ will apply rule of reason analysis to Medicare ACOs. The CMS eligibility criteria are broadly consistent with the indicia of clinical integration that the FTC and DOJ have defined. The belief is that MSSP ACOs are likely to be genuine arrangements to reduce the cost of providing healthcare. CMS is charged with monitoring the MSSP ACO results. The Medicare ACO Policy Statement is focused on clinical integration and does not discuss financial risk sharing in any detail.

The Policy Statement sets out safety zones, requiring combined shares of not more than 30% for each common service. The Statement defines markets and services based on physician specialties and CMS definitions of major diagnostic categories—which are not necessarily reflective of market realities. Other requirements include:

  • Hospitals, ambulatory surgery centers and dominant participants must be nonexclusive.
  • Physicians may be exclusive unless they have more than 50% market share. (This is subject to an exception if there is just one physician in a particular specialty serving an area.)

Not many ACOs have invoked the safety zone in their CMS applications, because it’s a complex and data-intensive process, particularly for physicians.

ACOs outside of the safety zone will be analyzed under the rule of reason. The FTC is unlikely to challenge unless the ACO has a very high market share and engages in conduct the guidance has stated should be avoided, including:

  • Preventing commercial payers from directing and incentivizing patients through steering and tiering
  • Tying sales of ACO services to commercial payers purchasing other services outside the ACO
  • Contracting exclusively with physicians, hospitals, etc.
  • Restricting a payer’s ability to make cost, quality and other information available to enrollees

The 2011 Policy Statement offers an expedited voluntary antitrust review for Medicare ACOs. No one has gone through that process yet, so there are no examples of the FTC or DOJ formally looking at a Medicare ACO to see whether it meets the standards for clinical integration. Therefore, ACOs that are outside the safety zone have to fall back on the principles in FTC advisory opinions, including:

  • Selective choice of participating providers
  • Development and implementation by network providers of clinical protocols addressing conditions covered by the network, as well as quality and efficiency goals and benchmarks
  • Creation of organizational infrastructure to facilitate provider collaboration, ensure practice pattern transparency and monitor compliance with clinical guidelines
  • Implementation of electronic health information technology to share clinical information
  • Development of a system to monitor physician compliance
  • A formal program for physician performance reviews, a corrective action program and sanctions for consistently failing to meet benchmarks
  • A process to maximize in-network referrals

Hybrid Models—Belt Plus Suspenders

Some networks qualify as both clinically integrated and financially integrated—described as a belt-and-suspenders approach. Since the basic aims of both financial and clinical integration are the same, it makes sense that networks would develop both types of integration. A clinical integration program will provide the data and coordination needed for an ACO to take on financial risk. A financially integrated ACO usually needs some sort of clinical integration to achieve the systems improvements that enable financial risk-taking.

Managing Antitrust Risk: Single-Entity Models

Single-entity models consist solely of providers who are affiliated with a single health system. The affiliation consists of ownership or control by a common parent entity of all the participating providers. The providers may be employees or exclusive to an entity owned or controlled by the parent. The providers cannot compete with each other, because they are all effectively part of the same entity. There is no basis for liability under Section 1 of the Sherman Act, because there is no agreement among independent contractors.

Managing Antitrust Risk: Messenger Models

If a network entity is neither clinically nor financially integrated, the remaining option is the messenger model. In the messenger model, there is no joint venture among the competitors. Each competitor must make its own decisions in a silo without knowing what its competitors are offering or accepting.

By definition, under the messenger model, the network entity does not negotiate on behalf of numerous providers. Instead, the network entity relays offers and acceptances between the parties—the providers and the payer. Participation in the network is tentative and subject to final acceptance by each provider of each specific payer or contract.    

ACO Twists

Many ACOs do not negotiate payer fee schedules. For example, under the MSSP and NextGen ACO models, CMS pays all providers at the standard Medicare fee schedules, which exist regardless of the ACO arrangement. Instead, these ACOs often negotiate only supplemental provisions regarding:

  • The care coordination process;
  • The addition of supplemental shared savings incentives (or shared losses); and
  • The applicable quality metrics to be monitored, as well as rewards or penalties for attaining or falling short of goals.

While the same antitrust rules apply, antitrust officials are less likely to be concerned when fee schedules are not being altered or renegotiated.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Manatt, Phelps & Phillips, LLP | Attorney Advertising

Written by:

Manatt, Phelps & Phillips, LLP

Manatt, Phelps & Phillips, LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.